Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer ...

Is Regeneron a good stock to buy now in light of a potential 23andMe acquisition? Here's a quick look at what it's paying for to find out. What Regeneron could get for $256 million 23andMe's ...

D.C. sue to block 23andMe's data sale amid bankruptcy proceedings. Regeneron Pharmaceuticals' $256 million acquisition faces ...

States sue to halt Regeneron's 23andMe acquisition, citing privacy concerns over user DNA data, as a court-ordered report on ...

WilmerHale said it’s representing the law professor tapped to make privacy-related recommendations about the sale of ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Lawmakers want to know what will be done to make sure consumer genetic testing company 23andMe’s data will stay out of the ...

The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

The sale of 23andMe's genetic database to Regeneron shows gaps in Australia's cross-border data protection laws for sensitive ...

The founder of 23andMe has asked a federal bankruptcy court judge to reopen an auction for the genetic testing company, ...

Me (OTC:MEHCQ) faces a second auction after a $305M bid challenges Regeneron's (REGN) initial bid for its assets. Read more ...